Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis

Scientific Reports
Yongfeng WangJianhua Yang

Abstract

ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB. However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation. Here we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy. In addition, AZD3463 enhanced the cytotoxic effects of doxorubicin on NB cells. AZD3463 also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models. These results indicate that AZD3463 is a promising therapeutic agent in the treatment...Continue Reading

References

Oct 17, 2008·Nature·Isabelle Janoueix-LeroseyOlivier Delattre
Oct 17, 2008·Nature·Yuyan ChenSeishi Ogawa
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm A SmithGregory H Reaman
Jun 19, 2010·The New England Journal of Medicine·John M Maris
Aug 20, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sara De BrouwerFrank Speleman
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Jun 28, 2011·Biochemical Pharmacology·Annick NotteCarine Michiels
Aug 16, 2011·The Biochemical Journal·Christina SchönherrBengt Hallberg
Sep 29, 2011·Seminars in Cancer Biology·Anna M AzarovaRani E George
Nov 11, 2011·Science Translational Medicine·Scott C BreslerYaël P Mossé
Dec 22, 2011·Cancer Letters·Roser FranciscoSantiago Ambrosio
May 16, 2012·Nature Reviews. Clinical Oncology·Erica L Carpenter, Yael P Mossé
May 17, 2012·International Journal of Clinical Oncology·Junichi Hara
Jan 9, 2013·Anti-cancer Agents in Medicinal Chemistry·Hui SunJuan Sebastian Yakisich
May 25, 2013·Nature Reviews. Cancer·Nai-Kong V Cheung, Michael A Dyer
Sep 7, 2013·Toxicology Letters·Jae Hyeon ParkHyun Chul Koh
Oct 30, 2013·Klinische Pädiatrie·J H SchulteA Eggert
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
Nov 27, 2014·Apoptosis : an International Journal on Programmed Cell Death·Huiyuan ZhangJianhua Yang
Dec 3, 2014·Biochemical and Biophysical Research Communications·Fei XuYong Sun
Mar 12, 2015·Cancer Cell·Frederick H WilsonLevi A Garraway
Jul 1, 2015·Cancer Research·Elizabeth R TuckerLouis Chesler

❮ Previous
Next ❯

Citations

Jan 27, 2018·Cell Death & Disease·Kadri ValterVladimir Gogvadze
Mar 4, 2020·Expert Opinion on Therapeutic Patents·Yi-Min LiuJing-Ping Liou
Dec 1, 2017·Cancers·Julie FrentzelSylvie Giuriato
Jan 17, 2019·Blood Cancer Journal·Sausan A MoharramJulhash U Kazi
Mar 21, 2018·Nature Communications·Sandra G Gonzalez MalagonKaren J Liu
Mar 29, 2018·Cell and Tissue Research·Laura E RitenourSharon J Diskin
Apr 5, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jyothi Dhuguru, Rachid Skouta
Dec 14, 2019·Applied Microbiology and Biotechnology·Zhenru XuJi Zhang
Jul 29, 2017·Molecular Cancer Therapeutics·Miho J FuseRyohei Katayama
Oct 29, 2020·Biochemical and Biophysical Research Communications·Bakiye Goker BagcaCigir Biray Avci
Aug 17, 2019·Journal of Medicinal Chemistry·Xiaotian KongTingjun Hou

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
flow cytometry
transfection

Software Mentioned

BD FACDiva

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis